1 completed, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow ARV-1801: new trials by email Literature Review of ARV-1801 trials Research Report on ARV-1801
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations Sodium Fusidate, Placebo - Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation | Phase 2 | Withdrawn | Aceragen | 2023-02-10 | 2023-07-19 | |
| Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients Ceftazidime or meropenem, ARV-1801, Placebo - Melioidosis | Phase 2 | Completed | Arrevus Inc. | 125 | 2022-06-14 | 2024-02-16 |
Cystic Fibrosis (1) · Melioidosis (1)
Aceragen (1) · Arrevus Inc. (1)
Thailand (1) · United States (1)